Practice manual issued for COVID-19 treatments in Korea
By | translator Kim, Jung-Ju
23.01.30 05:50:31
가나다라
0
KSAT publishes a guideline for easy application in the medical field
Overcomes the limitations of existing guidelines that contain too much information including a list of contraindicated drugs
“Shows clear benefit in reducing progression to severe disease in patients with mild COVID-19 symptoms... should be actively prescribed in high-risk groups."
Doctors have issued a ‘Practice Manual’ to provide an understanding of how to use the COVID-19 treatment in one glance. The manual was prepared to directly address difficulties HCPs experienced prescribing COVID-19 treatments in the field due to a large number of contraindicated drugs.
The Korean Society for Antimicrobial Therapy (KSAT) recently distributed a manual for the actual prescription of Paxlovid, Pfizer's oral COVID-19 treatment. The manual was designed to allow easier understanding for HCPs on whether to refrain prescription of Paxlovid or make dosage adjustments according to a patient's medication status.
Paxlovid is the first oral COVID-19 treatment that was approved in Korea.
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)